Ribomic Inc. (TYO:4591)
Japan · Delayed Price · Currency is JPY 72.00
-1.00 (-1.37%)
Jul 16, 2026, 10:05 AM JST
Ribomic Revenue
In the fiscal year ending March 31, 2026, Ribomic had annual revenue of 3.00M JPY with 50.00% growth. Ribomic had revenue of 2.25M in the quarter ending March 31, 2026.
Revenue
3.00M
Revenue Growth
+50.00%
P/S Ratio
1,361.42
Revenue / Employee
120.00K
Employees
25
Market Cap
4.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.00M | 1.00M | 50.00% |
| Mar 31, 2025 | 2.00M | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | 65.00M | -15.00M | -18.75% |
| Mar 31, 2022 | 80.00M | -11.00M | -12.09% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.17B |
| Kohjin Bio | 4.94B |
| Soiken Holdings | 4.40B |
| PRISM BioLab Co.,LTD | 711.65M |
| Carna Biosciences | 619.35M |
| Chiome Bioscience | 601.75M |
| D. Western Therapeutics Institute | 305.97M |
| Kringle Pharma | 73.00M |